Study questions need for frequent blood tests in common arthritis drug
NCT ID NCT07512401
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at over 2,400 people with rheumatic diseases who take methotrexate. Researchers compared those who had standard lab monitoring to those who had fewer blood tests. The goal was to see if reduced monitoring is as safe in terms of preventing organ damage or death.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could show that less frequent lab monitoring is safe, potentially reducing burden on patients and healthcare systems.
- What could go wrong
- This is an observational study, not a controlled trial, so it can't prove cause and effect. Results may not apply to all patients or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATIC DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could early lipid screening in High-Risk kids prevent future heart attacks?
- Community leaders step up to boost COVID shots in black rheumatic patients
- Can Sauna-Like heat help chronic pain? new study investigates
- Text reminders and calls help veterans take lifesaving pills
- New registry aims to unlock safer pregnancies for women with autoimmune conditions
- Which exercise focus works best for kids with rheumatic conditions?